DeepMed Research

Xspray Pharma AB

🇸🇪Sweden

Country: 🇸🇪Sweden

Ownership: Public

Established: 2003-01-10

Employees: 26

Market Cap: -

Website: https://xspraypharma.com

Clinical Trials

An Drug-drug Interaction Study to Evaluate the Effects of Omeprazole 40mg on the Pharmacokinetics of SPRYCEL®

Phase 1

Completed

Conditions: Drug-drug Interaction Study

Interventions: Drug: SPRYCEL® (dasatinib) 100 mg Film-Coated Tablets in combination with Omeprazole Delayed-Release Capsules USP, 40 mg

First Posted Date: 2023-11-24

Last Posted Date: 2023-11-24

Lead Sponsor: Xspray Pharma AB

Target Recruit Count: 18

Registration Number: NCT06145217

Locations: 🇮🇳
QPS Bioserve India Pvt Limited, Hyderabad, India

Evaluating the Pharmacokinetic Parameters and Relative Bioavailability of Sorafenib (XS005) in Healthy Male Subjects

Phase 1

Completed

Conditions: Pharmacokinetics
Bioavailability

Interventions: Drug: Sorafenib - Period 1
Drug: Sorafenib - Period 2
Drug: Sorafenib - Period 3
Drug: XS005 Sorafenib Tablet A - Period 2
Drug: XS005 Sorafenib Capsule A - Period 1
Drug: XS005 Sorafenib Capsule A - Period 2
Drug: XS005 Sorafenib Capsule A - Period 3
Drug: XS005 Sorafenib Tablet A - Period 1
Drug: XS005 Sorafenib Tablet A - Period 3

First Posted Date: 2023-08-01

Last Posted Date: 2023-08-01

Lead Sponsor: Xspray Pharma AB

Target Recruit Count: 15

Registration Number: NCT05967377

Locations: 🇬🇧
Quotient Sciences, Nottingham, United Kingdom

Comparative Bioavailability of XS004 (Dasatinib) Formulation G and SPRYCEL® (Dasatinib) in Healthy, Adult Subjects Under Fasting Conditions

Phase 1

Completed

Conditions: Biological Availability

Interventions: Drug: Dasatinib ASD 100 mg
Drug: Dasatinib 140 MG [Sprycel]

First Posted Date: 2022-06-30

Last Posted Date: 2022-06-30

Lead Sponsor: Xspray Pharma AB

Target Recruit Count: 110

Registration Number: NCT05439408

Locations: 🇮🇳
QPS Bioserve India Pvt Limited, Hyderabad, India

Evaluating the Effects of Omeprazole on the Pharmacokinetics of XS004 (Dasatinib) Tablets in Healthy Adult Subjects Under Fasting Conditions

Phase 1

Completed

Conditions: Pharmacokinetics
Drug Interactions

Interventions: Drug: Dasatinib ASD
Drug: Omeprazole 40 MG

First Posted Date: 2022-06-27

Last Posted Date: 2022-06-27

Lead Sponsor: Xspray Pharma AB

Target Recruit Count: 17

Registration Number: NCT05433896

Locations: 🇺🇸
AXIS Clinicals, Dilworth, Minnesota, United States

Prev
1
Next

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy